🌟 Speaker Announcement We’re excited to announce Dr. Mireia Crispin from the University of Cambridge and 52North - creators of Neutrocheck® as a speaker for #OxML2025 MLx Health & Bio! 📢 Topic: Multiomics 📅 Dates: 2–5 August 📍 Location: University of Oxford’s Maths Institute & Online MLx Health & Bio is a masterclass focusing on cutting-edge theoretical machine learning and its transformative applications in healthcare and biomedical sciences. Join us and learn from leading researchers from academia and industry as they share their latest insights and breakthroughs. REGISTER HERE: oxfordml.school #OxML #MLxHealth #AI #Multiomics #BiomedicalAI #aiinhealth #aiwearables @mireiacrispin @UniofOxford @Cambridge_Uni @52NorthHealth

🚀 Meet @52NorthHealth, the oncology-focused medtech who have just raised $6m! 🚀 The Cambridge-based team is developing Neutrocheck: a device that helps monitor Neutropenic sepsis, the most fatal side-effect of chemotherapy treatment. Excited to join hands with @KhpVentures and @CedarsSinai to help 52North to reduce pressure and inequality in healthcare systems worldwide. Best of luck to all at @52NorthHealth with your next steps! Find out more here: 👉 bit.ly/41dHkmM #OnMyHorizon @saifahmad_uk, @UCamEnterprise, @macmillancancer , @nikkiweckman

🎙️ Meet Umaima Ahmad, #Cambridge alumna & co-founder of medtech startup, 52North. Her company has created Neutrocheck®, an easy-to-use app that allows chemo patients to test their blood on the move. 🔗 cam.ac.uk/stories/caring-for… #NWEW #WomensEnterpriseWeek #CambridgeAlumni #Cancer

Great to see two #AccelerateCambridge alumni @UpfrontDx and @52NorthHealth - creators of Neutrocheck® have been selected for The Innovative Devices Access Pathway (IDAP), a pioneering initiative aimed at revolutionising healthcare delivery within the NHS - gov.uk/government/publicatio…

Here’s Umaima Ahmad, CEO of 52 North, talking about the wave of success her company is riding and the value she places on Innovate UK support. Watch the full story of Neutrocheck, 52 North’s innovation that will improve cancer patients’ lives: 📽️ youtu.be/lWeYJO1ov6c

#InnovationSpotlight: 52 North Health have developed Neutrocheck, at-home finger-prick blood test to identify those at risk of potentially life-threatening neutropenic sepsis. Find out more about how the device will help support patients with cancer: easternahsn.org/impact-story…

The first showcase in our portfolio is @52NorthHealth. A low cost, portable finger prick blood test and digital platform to detect people at risk of Neutropenic sepsis. Neutrocheck has the potential to save 2000 lives a year & prevent 250,000 unnecessary A&E visits

#InnovationsInHealthcare 💡#Cancer Neutropenic sepsis (NS) currently kills 3 people in England & Wales every day. Neutrocheck by 52North helps identify #chemotherapy patients at risk of NS through a simple home finger-prick blood test.

Each fortnight we are highlighting one of the #21toWatch Top21.2023. @dramafrimpong was named @TheIET’s (IET) Young Woman Engineer of the Year. She manages the @52NorthHealth engineering teams in the development of NeutroCheck. Watch her presentation: ow.ly/B9Jf50NzuKv

#21toWatch Top21.2023 winner @dramafrimpong was named the Institution of Engineering and Technology’s (IET) Young Woman Engineer of the Year. She also manages the 52 North Health engineering teams in the development of NeutroCheck

Congratulations to our partner @52NorthHealth! @macmillancancer has invested in Neutrocheck, a simple low-cost test and #digitalplatform that provides a rapid and reliable result at-home, helping doctors to identify patients at risk of #neutropenicsepsis: nhscep.com/2023/02/07/macmil…

Macmillan invests in Neutrocheck device for home-testing neutropenic sepsis med-technews.com/news/medtec… #medtech #neutropenicsepsis #digitalhealth #cancer

Reminder of our first story of the day: @macmillancancer has invested in Neutrocheck, a portable device and app being developed by 52 North Health, to help people with cancer test for neutropenic sepsis from their own homes. Full story 👉 ow.ly/ss5250MNW3n

Congratulations to portfolio company #52NorthHealth on receiving the first-ever venture capital investment from @macmillancancer. The £100k will help advance the company’s #NeutroCheck device to trials. thetimes.co.uk/article/cance…

Congratulations to Clinical Entrepreneur Saif Ahmad and the team at 52North - creators of Neutrocheck®. Macmillan Cancer Support, the leading UK cancer charity, has invested in Neutrocheck® – a portable device and accompanying app. thetimes.co.uk/article/cance… @DrTonyYoung #NHSCEP

Today we ⁦⁦launch our Innovation Impact Investment Portfolio by announcing our investment in 52North - creators of Neutrocheck® a pioneering at-home neutropenic sepsis test. More in post below 😊👇🏼 #cancer ⁦⁦@macmillancancer⁩ linkedin.com/posts/tanya-hum…

UKST CEO Ron Daniels said: “It’s great to see that 52North Health’s NeutroCheck device is attracting investment from @macmillancancer – The UK Sepsis Trust has been part of the research team advising on how best to integrate the product into clinical pathways." (1/2)

Macmillan have an innovation investment fund where we invest in products that could have a transformational impact for people with cancer. Here's some coverage of of our 1st investment in Neutrocheck a company looking at early warning of Neutropenic sepsis justentrepreneurs.co.uk/news…

- @macmillancancer, the leading UK cancer charity, has invested in @Neutrocheck® – a portable device and accompanying app – with the aim to help people with cancer test their risk of life-threatening neutropenic sepsis at home. Read more👉 buff.ly/3DIPVky #startupnews

Cancer treatment gets boost from med-tech development @nikkiweckman @saifahmad_uk @mireiacrispin @UKSepsisTrust @UCamEnterprise @macmillancancer #52North #NeutroCheck #sepsis #medtech #startup bv.world/tech/cutting-edge/2…